Sebaceous Carcinoma: Mohs Indications & Treatment

Sebaceous carcinoma (SC) is a rare, aggressive cutaneous adnexal neoplasm arising from sebaceous glands. It accounts for approximately 0.7% of all eyelid tumors and 1-5% of eyelid malignancies in Western populations, making it the third most common eyelid malignancy after basal cell carcinoma and squamous cell carcinoma. In Asian populations, SC represents a proportionally higher fraction of eyelid malignancies (up to 33% in some series), likely reflecting both lower BCC incidence and genetic predisposition. The overall incidence in the United States is estimated at approximately 1-2 per 1,000,000 person-years. SC demonstrates a predilection for the periocular region, with approximately 75% of cases arising from the eyelids. Specifically the meibomian glands (tarsal plate) or glands of Zeis (eyelash follicles). The upper eyelid is affected 2-3 times more frequently than the lower eyelid, corresponding to the higher density of meibomian glands in the upper tarsal plate (approximately 25 in the upper lid vs. 20 in the lower lid). Extraocular SC accounts for approximately 25% of cases and can arise anywhere sebaceous glands are present, with the head and neck being the most common extraocular site. The median age at diagnosis is 65-73 years, with a slight female predominance (approximately 1.4:1 female-to-male ratio) in periocular SC. Risk factors include prior radiation therapy to the head and neck region, immunosuppression (including solid organ transplant), and Muir-Torre syndrome. Notably, unlike most cutaneous malignancies, UV radiation has not been established as a primary etiologic factor for SC, though some studies suggest a contributing role.

The clinical presentation of sebaceous carcinoma is notoriously deceptive, earning it the designation as a "great masquerader" in ophthalmologic and dermatologic literature. Periocular SC typically presents as a firm, painless, yellowish nodule on the eyelid, often centered in the tarsal plate when arising from meibomian glands. However, the most clinically significant feature of SC is its ability to mimic benign conditions, leading to diagnostic delay averaging 1-3 years from symptom onset to definitive diagnosis. SC frequently masquerades as a chalazion (the single most common misdiagnosis), chronic blepharoconjunctivitis, basal cell carcinoma, squamous cell carcinoma, or meibomian gland dysfunction. The presence of pagetoid intraepithelial spread. A hallmark of SC. Can produce diffuse conjunctival injection and thickening that mimics chronic conjunctivitis, further delaying the diagnosis. Unilateral chronic blepharoconjunctivitis that fails to respond to conventional therapy should always raise suspicion for SC. Multicentric growth is another characteristic pattern, with discontinuous tumor foci separated by clinically normal-appearing tissue, which can lead to incomplete excision if not recognized. Loss of eyelashes (madarosis) in the region of the tumor is an important clinical clue, as is yellow discoloration of the overlying skin reflecting the lipid content of sebaceous differentiation. Extraocular SC presents as a flesh-colored to yellowish papule or nodule, often on the head and neck, and may be clinically indistinguishable from BCC, SCC, or other adnexal tumors.

Histopathologically, sebaceous carcinoma is characterized by lobules, sheets, and irregular infiltrating nests of basaloid to eosinophilic cells exhibiting variable degrees of sebaceous differentiation. The hallmark feature is the presence of intracytoplasmic lipid vacuoles that indent the nucleus, producing the characteristic "mulberry" or "scalloped" nuclear contour seen in sebocytes. The degree of sebaceous differentiation varies from well-differentiated tumors (with abundant mature sebocytes containing large lipid vacuoles) to poorly differentiated tumors (with predominantly basaloid cells and only focal lipid vacuolation). Comedonecrosis. Central necrosis within tumor lobules resembling the necrosis seen in comedo-type ductal carcinoma in situ of the breast. Is a characteristic finding. Pagetoid intraepithelial spread (also termed pagetoid invasion) is a critical histologic feature in which individual tumor cells or small clusters spread through the overlying epidermis and conjunctival epithelium in a pattern resembling Paget disease. Pagetoid spread is present in 44-80% of periocular SC cases and can extend for several millimeters or even centimeters beyond the invasive tumor component, creating "skip areas" of involvement that complicate margin assessment.

Muir-Torre syndrome (MTS) is an autosomal dominant cancer predisposition syndrome defined by the co-occurrence of at least one sebaceous neoplasm (including sebaceous adenoma, sebaceoma, or sebaceous carcinoma) and at least one visceral malignancy. MTS is a phenotypic variant of Lynch syndrome (hereditary nonpolyposis colorectal cancer, HNPCC) and is caused by germline mutations in DNA mismatch repair (MMR) genes, most commonly MSH2 (approximately 90% of MTS cases) and MLH1, with rare cases involving MSH6 and PMS2. Loss of MMR protein function leads to microsatellite instability (MSI), which drives tumorigenesis in both cutaneous and visceral tumors. Approximately 30-60% of patients with sebaceous carcinoma have been reported to harbor MMR deficiency on immunohistochemistry or MSI on molecular testing, though not all of these represent germline mutations (some are somatic/sporadic). The visceral malignancies most commonly associated with MTS include colorectal carcinoma (the most frequent, occurring in approximately 56% of MTS patients), genitourinary malignancies (22%), breast cancer, and hematologic malignancies. Visceral malignancies may precede, occur simultaneously with, or follow the sebaceous neoplasm. The clinical significance for the Mohs surgeon is that every patient diagnosed with SC should be evaluated for MTS by performing MMR immunohistochemistry (for MLH1, MSH2, MSH6, PMS2) on the tumor specimen as a screening step.

Sebaceous carcinoma of the eyelid is staged using the AJCC 8th Edition TNM staging system for carcinoma of the eyelid, which differs from the staging system used for cutaneous carcinomas at other sites. Extraocular SC is staged using the AJCC system for cutaneous squamous cell carcinoma of the head and neck or the general cutaneous carcinoma staging system, depending on location. The AJCC 8th edition eyelid carcinoma staging system incorporates tumor size, depth of invasion, and involvement of adjacent structures. Several clinicopathologic features have been identified as high-risk indicators that independently predict local recurrence, regional metastasis, and disease-specific mortality.

Mohs micrographic surgery is increasingly recognized as the preferred surgical modality for sebaceous carcinoma, particularly in the periocular region where tissue conservation is paramount and the complex anatomy of the eyelid makes predetermined wide margins impractical. The AAD/ACMS Appropriate Use Criteria (AUC) support the use of Mohs surgery for SC, and multiple retrospective series have demonstrated lower local recurrence rates with Mohs compared to wide local excision (approximately 11-12% for wide excision vs. 4-6% for Mohs in periocular SC). However, Mohs for SC carries unique challenges that distinguish it from Mohs for BCC or SCC, primarily related to the difficulty of detecting pagetoid intraepithelial spread and poorly differentiated SC cells on standard H&E frozen sections.

The management of sebaceous carcinoma requires a multidisciplinary approach integrating dermatologic surgery, oculoplastic surgery, radiation oncology, medical oncology, and genetic counseling. The treatment algorithm is guided by tumor stage, location (periocular vs. extraocular), presence of high-risk features, and patient factors including comorbidities and functional status.

The prognosis of sebaceous carcinoma depends heavily on tumor stage, location, histologic differentiation, and the presence of high-risk features. Overall, periocular SC carries a local recurrence rate of approximately 6-36% (highly dependent on surgical modality and margin assessment technique), a regional metastatic rate of approximately 8-25%, a distant metastatic rate of approximately 3-8%, and a disease-specific mortality rate of approximately 5-15%. Mohs surgery with immunostain-guided margins has significantly improved local control, with recurrence rates of approximately 4-6% in recent series. Substantially lower than the 11-36% range reported for wide excision with standard margin assessment. Extraocular SC generally carries a somewhat more favorable prognosis than periocular SC, with lower rates of local recurrence and metastasis, though this may partly reflect lead-time bias and earlier detection at non-eyelid sites. Poorly differentiated histology, tumor size >20mm, lymphovascular invasion, and orbital invasion are the strongest negative prognostic factors. Patients with Muir-Torre syndrome may have a paradoxically better SC-specific prognosis than sporadic SC patients, though they face cumulative morbidity from multiple synchronous and metachronous malignancies.